Back to top
more

uniQure (QURE)

(Delayed Data from NSDQ)

$7.43 USD

7.43
1,362,950

+0.27 (3.77%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $7.44 +0.01 (0.13%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 18.75% and 16.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of 38.89% and 2.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi

by Zacks Equity Research

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?

by Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 6.45% and 221%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

by Zacks Equity Research

IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Soars on New Huntington's Disease Study Data

by Zacks Equity Research

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)

by Zacks Equity Research

uniQure (QURE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance

by Zacks Equity Research

The FDA decision on Pfizer's (PFE) BLA for marstacimab for hemophilia A and B is expected in the fourth quarter of 2024, while the European Commission's decision is expected in 2025.

Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for uniQure (QURE) points to a 405.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -26.17% and 57.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

by Ekta Bagri

Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

by Zacks Equity Research

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing

by Zacks Equity Research

A final decision on Pfizer's (PFE) BLA filing, seeking approval for hemophilia B gene therapy, treatment is expected by second-quarter 2024.